HERZLIYA PITUACH, Israel--(BUSINESS WIRE)--Arkin Holdings, the largest and leading Israel-based life sciences investor, today announced a new partnership, Arkin Bio-Ventures II, to be funded with $140 million in capital commitments, from Arkin Holdings as well as an investor group including Migdal and Phoenix Group. The fund plans to invest in 10 to 12 private companies developing groundbreaking therapies such as gene therapy, RNA/DNA-based therapy, and targeted therapies for indications with high unmet medical needs.
“Arkin Bio-Ventures II builds on the success of our earlier, well-established and lucrative fund. Together with our partners, we look forward to further successful investments in novel and world class technologies and organizations,” said Mori Arkin, founder and chairman of Arkin Holdings. "We are excited to collaborate with Migdal and Phoenix Group, two of Israel's largest and most sophisticated institutional investors.”
The new fund will be managed by Pini Orbach, Ph.D., Head of Pharma at Arkin Holdings and Alon Lazarus, Ph.D will be the investment manager of the Fund. Elad Givoni, Head of Private Equity at Phoenix Group; Asaf Gherman, Head of Alternative Investments at Migdal; and Aviad Shimon, Head of Private Equity at Migdal led the venture on behalf of the institutional investors.
Dr. Orbach, manager of Arkin Bio Ventures II, commented, “Inspired by recent scientific breakthroughs, Arkin Bio-Ventures II is well positioned to meaningfully expand its pharma investment capabilities and global reach, to capture innovative technologies and companies that could have a strong impact on medicine and provide new therapies for patients.”
Additional information may be found on Arkin Holdings' website: http://www.arkinholdings.com
About Arkin Holdings
Arkin Holdings, managed by Nir Arkin, is the largest and leading Israel-based life sciences investor. Founded by Mori Arkin, Arkin Holdings has successfully made strategic investments in a number of private pharma and biotech companies, including public companies Solgel (Nasdaq:SLGL) and Urogen (Nasdaq:URGN) and more than 10 private companies including , cCAM Biotherapeutics , Keros Therapeutics, Censa Pharmaceuticals and Oncorus.
